Brief: Bioarctic Says FDA Accepts Filing Of Leqembi Sbla For IV Maintenance Dosing

BioArctic AB

10/06/2024 24:39

June 9 (Reuters) - Bioarctic Ab  BIOAb.ST :
    * FDA ACCEPTS FILING OF LEQEMBI ®  (LECANEMAB-IRMB) SBLA FOR
IV
MAINTENANCE DOSING FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE
    * PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE IS SET
FOR
JANUARY 25, 2025

Source text for Eikon:  ID:nWkr1F5S2x 
Further company coverage:  BIOAb.ST 

 ((Reuters.Briefs@thomsonreuters.com;))